Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabapentin for Opioid and Alcohol Abuse
NCT03205423Phase 2Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Aug 2017
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of gabapentin in opioid use disorder (OUD) and alcohol use disorder (AUD) (2 arms), sponsored by New York State Psychiatric Institute. Primary endpoint: Peak Positive Subjective Responses to Drug Challenges at 360 minutes. Started Aug 2017; status: completed.
02
Drugs
gabapentin
03
Conditions
opioid use disorder (OUD)alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT03205423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03205423.